tbuckley/cabot-search huggingface dataset:
This Week in &lt;emph&gt;JAMA&lt;/emph&gt;
Journal: JAMA (2011)

A Piece of My Mind"A physician really doesn't want to have 'favorites' and for good reason strives daily to treat everyone with equal effort and compassion."From "The Leopard-Skin Bra." SEE PAGE 756 Medical News & PerspectivesDespite conflicting results, 2 clinical studies prompt a new hypothesis that adjuvant treatment with the bisphosphonate zoledronic acid might improve survival in some postmenopausal women with breast cancer.
Clinical utility of circulating tumor DNA (ctDNA) in resectable pancreatic ductal adenocarcinoma (PDAC).
Authors: Hui-Li Wong, Kevin Bushell, Joanna Karasinska, Sarah Arthur, Ryan Morin, David F. Schaeffer, Daniel John Renouf
Journal: Journal of Clinical Oncology (2016)

e23043 Background: ctDNA is emerging as a promising biomarker, with potential utility in screening, detecting minimal residual disease after curative resection and monitoring treatment response or resistance in advanced disease. Here we perform sequential ctDNA quantification in patients (pts) with resectable PDAC using a novel and highly sensitive multiplex technology to explore the clinical utility of ctDNA as a diagnostic and prognostic biomarker. Methods: Banked plasma and tumor samples from 18 pts with resected PDAC were retrieved. Plasma samples were collected 0-28 days before, and 28-70 days after surgery. DNA was extracted using standard protocols and analyzed using the OnTarget system, which enriches for DNA molecules containing hot spot mutations prior to sequencing. A 96-plex panel that includes the most prevalent mutations in KRAS, PIK3CA and TP53 was used. Results: 16 pts (89%) had at least 1 mutation detected by OnTarget in the tumor sample, most frequently in KRAS codon 12 (n = 14). 2 tumors harbored GNAS mutations; both had arisen from intrapapillary mucinous neoplasms. ctDNA was detected in pre-operative blood in 7 pts; 1 was a variant that was not present in tumor and was excluded from further analysis. Sensitivity of pre-operative ctDNA was 40% (6/15). There was no correlation between pre-operative ctDNA and tumor pathologic features or CA19-9 levels. At median follow-up of 13.5 months, there was no difference in recurrence-free survival (RFS) between pts with and without detectable pre-operative ctDNA (p = 0.832). Of the 9 available post-operative blood samples, 1 had a GNAS R201H mutation that was not present in the tumor. Concordant plasma mutations were detected post-operatively for 3 pts, all of whom had recurred. RFS was significantly shorter in pts with concordant ctDNA detected after surgery (median 2.1 vs 14.4 months, p = 0.004). Conclusions: Pre-operative ctDNA has low sensitivity, suggesting limited utility in PDAC screening, and does not appear to be prognostic. RFS was significantly longer in pts without detectable post-operative ctDNA; however this analysis is limited by small numbers and short follow-up. The significance of discordant plasma and tumor mutations is unknown.
Conformational Analysis of Environmental Agents: Use of X-Ray Crystallographic Data to Determine Molecular Reactivity
Authors: Vivian Cody
Journal: Environmental Health Perspectives (1985)

This paper explores the use of crystallographic techniques as an aid in understanding the molecular reactivities of a number of agents that are of concern to pharmacologists and toxicologists. The selected examples demonstrate the role of structural data in the determination of absolute configuration, configurational flexibility and active-site topology for a reactive species. For example, the role of absolute stereochemistry in understanding synthetic pyrethroid structure-activity relationships is shown from analysis of their crystal structures; conformational flexibility among DDT analogues, and the importance of conformational and electronic properties in phenylalkanoic acid herbicides are shown from systematic analysis of their crystal structures; and interpretation of active-site stereochemistry is made by study of computer modeling of enzyme inhibitors in the active sites of related protein crystal structures. Thus, the observed patterns in conformational flexibility and their resultant effects on substrate pharmacological profile can be interpreted in understanding the molecular level events that influence biological reactivity.
Croonian Lectures on LIVER AND SPLEEN: THEIR CLINICAL AND PATHOLOGICAL ASSOCIATIONS
Authors: J. W. McNee
Journal: BMJ (1932)

Immediately after recovery from the anaesthetic the patient's own words were: " I feel more alive."He answered questions immediately, and his stammer- ing, which had worried him before operation, had disappeared.His face had improved in appearance in that the mask-like expression had more or less disappeared.When he was able to walk, two days after operation, it was found that his right arm swung normally, and there was no, limp or rigidity apparent; his reflexes had returned to normal.On March 10th he was eating well-he had not cared for food before operation.He had no hesitancy about speech; he laughed spontaneously, and could carry on an intelligent conversation.
Hb Iraq‐Halabja β10 (A7) Ala→Val (GCC→GTC): A new β‐chain silent variant in a family with multiple Hb disorders
Authors: S. Deutsch, R. Darbellay, R. Offord, A. Frutiger, J. Kister, H. Wajcman, Ph. Beris
Journal: American Journal of Hematology (1999)

A patient originating from Iraq was referred to our laboratory upon suspicion of a hemoglobinopathy. Routine hematological tests revealed a microcytic and slightly anemic phenotype with an elevated HbA2 suggestive of β-thalassemia. Samples were obtained for several members of the family which upon examination revealed highly heterogeneous phenotypes that prompted us to investigate the case further. Sequencing of the β-globin gene and α cluster mapping in the propositus and his brother showed a previously undescribed β-globin variant:Hb Iraq-Halabja, β10(A7) Ala→Val (GCC→GTC), associated with β0-thalassemia IVS-2 nt1 G→A and either α-thal-2-3.7 kb deletion (brother), or α-globin gene triplication anti-3.7 kb type (propositus). Detailed functional studies of the variant gave a normal oxygenation curve, a normal heterotopic action of 2,3 DPG, and normal heat stability and isopropanol precipitation tests. The variant shows a clear difference in migration properties compared to normal β-chain only when run on PAGE urea Triton. As expected, α/β-globin mRNA ratios were influenced by the concomitant presence of an α-globin gene pathology and the β0 thalassemia and not by the presence of the β-globin variant which apparently is clinically silent. Am. J. Hematol. 61:187–193, 1999. © 1999 Wiley-Liss, Inc.
Lippincott's Blood-Pressure and Clinical Charts.
Journal: JAMA (1913)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
HEALTH IN MICHIGAN.
Journal: JAMA (1884)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Stereotyped Behavior of the Infant Chimpanzee
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Erratum
Authors: Jie Li, Chunyue Yin, Hiroaki Okamoto, Harry Mushlin, Brian M. Balgley, Cheng S. Lee, Kristy Yuan, Barbara Ikejiri, Sven Glasker, Alexander O. Vortmeyer, Edward H. Oldfield, Robert J. Weil, Zhengping Zhuang
Journal: Neuro-Oncology (2008)
Disruption and Meaning
Journal: JAMA (1998)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract 3996: Search for prognosis prediction factors in treatment selection for elderly patients with EGFR negative advanced stage non-small cell lung cancer patients
Authors: Yoshiko Kaneko, Takako Mouri, Nobuyo Tamiya, Tadaaki Yamada, Junji Uchino, Koichi Takayama
Journal: Cancer Research (2019)

Abstract Introduction: Since 40% of Japanese lung cancer patients are older than 75 years old, it is necessary to consider a specific strategy to treat such elderly lung cancer patients. From that aspect, it is very important to define frail or vulnerable elder populations who have lots of heterogenic health background in treatment of lung cancer. In this study, we have tried to identify prediction factors which significantly correlates to overall survival (OS) of such elderly advanced lung cancer patients by using of patient status and laboratory data before treatment. Objects and methods: Patients more than 75 years old who enrolled in this retrospective study were diagnosed as an advanced and EGFR negative non-small cell lung cancer during 2013-2017, and they were not available for any molecular targeted therapeutics. OS of best supportive care (BSC) cohort and chemotherapy with Docetaxel monotherapy and more cohort from those elderly patients were analyzed by Kaplan-Meier analysis. Results: Clinical Question 1; What is a prediction factor for OS of BSC patients? Answer 1; From analysis of 29 BSC patients (age 15-94 years old, median 82), it is revealed that low performance status (PS =0,1) stage at diagnosis (p=0.03) are significantly correlated to longer OS, and also hypoalbuminemia is significantly correlated to worse OS (11 wks vs 35 wks). Age at diagnosis did not correlate to duration of OS. ( more vs less than 80 years old:15 wks vs 37 wks, P=0.13)Clinical Question 2; Does chemotherapy significantly prolong OS of elderly patients? Answer 2; Kaplan-Meier analysis of elderly patients (PS 0-2) less than 80 years old who were treated by chemotherapies at least with DOC monotherapy showed longer OS than that of 29 BSC patients ( 84 wk vs 15 wk, p=0.006). However, no significant difference to OS (p=0.378) has been observed to BSC patients in advanced stage with better PS (0-2). Multivariate analysis for OS indicated significant correlation of hypoalbuminemia (p=0.002), but no correlation of chemotherapy (p=0.202) has been observed. Conclusion: 1, EGFR mutation-negative advanced NSCLC patients elder than 80 years old who were treated by chemotherapies did not showed significantly longer OS than that of BSC patients. 2, PS and hypoalbuminemia before treatment may be prediction factors for longer OS of elder lung cancer patients. Citation Format: Yoshiko Kaneko, Takako Mouri, Nobuyo Tamiya, Tadaaki Yamada, Junji Uchino, Koichi Takayama. Search for prognosis prediction factors in treatment selection for elderly patients with EGFR negative advanced stage non-small cell lung cancer patients [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 3996.
Hemorrhagic Diseases
Authors: Walter B. Frommeyer, Robert D. Epstein
Journal: New England Journal of Medicine (1949)

THE subject of hemorrhagic disease is considered under the general headings of problem in diagnosis, hypotheses concerning hemostasis in normal subjects, diagnostic procedures, history, physical examination, basic examination of blood, urine and stool, measurement of capillary fragility, bleeding time, platelet count, clot retraction, measurement of coagulation and clotting times of venous blood, clotting time of recalcified plasma, screening tests for abnormal coagulation, determination of prothrombin activity, prothrombin consumption and determination of fibrinolysis.Problem in DiagnosisThe physician is called upon to diagnose and treat patients with signs and symptoms of an increased tendency to bleed. The manifestations of hemorrhagic diathesis . . .
Abstract 4326: Phosphatidylserine-targeting ‘betabodies’ for the treatment of cancer.
Authors: Xianming Huang, Dan Ye, Troy Luster, E Sally Ward, Philip Thorpe
Journal: Cancer Research (2013)

Abstract Bavituximab is a chimeric monoclonal antibody that is being combined with chemotherapy to treat patients with lung or pancreatic cancer in randomized Phase II clinical trials. Bavituximab targets the immunosuppressive lipid, phosphatidylserine (PS), which becomes exposed on the outer membrane surface of tumor blood vessels and tumor cells in tumors responding to therapy. The antibody acts by destroying tumor vasculature and by reactivating tumor immunity. Here, we generated new PS-targeting therapeutics by fusing domains of the PS-binding plasma protein, mouse β2-glycoprotein I (β2GP1), to the Fc region of mouse IgG2a. Such ‘betabodies’ potentially have the following advantages: they bind directly to PS, and do not require a cofactor protein (β2GP1) for binding; they can be made fully human; they are smaller in size (100 KDa); and they have slower blood clearance rates. A construct was generated that bound strongly to PS-expressing cells and plates, localized to tumor vascular endothelium in vivo, and had a β-phase blood half-life of approximately five days after intravenous injection into mice as compared with one day for a murine version of bavituximab, 2aG4. Betabodies could potentially be the next generation of PS-targeting cancer therapeutics. Citation Format: Xianming Huang, Dan Ye, Troy Luster, E Sally Ward, Philip Thorpe. Phosphatidylserine-targeting ‘betabodies’ for the treatment of cancer. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 4326. doi:10.1158/1538-7445.AM2013-4326
Rehabilitation Medicine
Authors: Henry H. Stonnington
Journal: JAMA (1989)

Physical medicine and rehabilitation as a specialty is 50 years old. In the last few years it has become one of the most significant growth areas in medicine. Ten years ago it was still hard to convince medical students that this was a field to consider. Now all "PM&amp;R" residency programs are filled with topranking students. The appearance of this "new" textbook is therefore highly significant, as it is a descendant of and has the same title as the textbook by Howard Rusk. Howard Rusk was one of the pioneers of this specialty. Therefore, this textbook by the successor of Howard Rusk and the New York University School of Rehabilitation Medicine is a major event. Dr Joseph Goodgold has produced an entirely new textbook. The authors of the various chapters are leaders in the field from throughout the country. The chapters deal with all aspects of the field of physical
Phase II study of everolimus in patients with thymoma and thymic carcinoma previously treated with cisplatin-based chemotherapy.
Authors: Paolo A. Zucali, Tommaso Martino De Pas, Giovannella Palmieri, Adolfo G. Favaretto, Antonio Chella, Marcello Tiseo, Michele Caruso, Matteo Perrino, Fabio De Vincenzo, Matteo Simonelli, Francesca Toffalorio, Piera Federico, Giulia Pasello, Marco Ali, Laura Giordano, Monica Bertossi, Armando Santoro
Journal: Journal of Clinical Oncology (2014)

7527 Background: Alterations of the serine-threonine kinase mammalian target of rapamycin (mTOR) signalling pathway are common in cancer, and thus mTOR is being actively pursued as a therapeutic target. In particular, mTOR is emerging as a potential target, following tumor responses observed in phase I trials, with recent data from several groups. The aim of this study is to determine the activity of Everolimus monotherapy in patients (pts) with advanced or recurrent thymoma (T) or thymic carcinoma (TC) previously treated with cisplatin-containing chemotherapy. Methods: Pre-treated T and TC pts were prospectively enrolled in single arm, single-stage, open label, multicentre, phase II trial. Pts received continuous treatment with oral everolimus 10 mg once daily until documented disease progression, unacceptable toxicity, or patient refusal. Tumour assessment was done every six weeks, safety was assessed every 21 days. A Fleming phase II trial was designed considering a disease control rate (DCR) of 40% or lower as clinically unworthy, whereas a rate of 60% or higher was considered of potential interest, α=β=0.10. It was calculated that 21 pts with disease control would be observed in the first 41 evaluable pts. Progression free survival (PFS), overall survival (OS), and safety were also evaluated. Results: Results of the first 35 enrolled pts are presented. Patient characteristics are as follow: median age is 51 years (range 37;81), male/female 20/15 (57%/43%), TC/T 12/23 (34%/66%), and locally advanced/metastatic disease 9/26 (26%/74%). We observed complete remission (CR) in 1 patient (TC), partial response (PR) in 3 pts (2TC/1T), and stable disease (SD) in 21 pts (16T/5TC), for a total of 25 pts who reached DC.With a median follow up of 10 months, median PFS was 12.1 months, while median OS was 24.0months. Seven pts (20%) presented a serious adverse event but only 3 of them permanently discontinued treatment. Conclusions: The primary end-point of this study was reached. These results suggest that Everolimus is able to achieve a satisfactory number of DC in this setting of pts. The efficacy should be better evaluated in subsequent larger study phases. Clinical trial information: NCT02049047.
A Full Representation.
Journal: JAMA (1884)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
EHA Guidance Document The process of CAR-T cell therapy in Europe
Journal: HemaSphere (2019)

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms. http://creativecommons.org/licenses/by-nc-sa/4.0